REVIEW A dual 5-alpha-reductase inhibitor that blocks both type 1 and type 2 5-alpha-reductase isoenzymes. These enzymes are responsible for converting testosterone into dihydrotestosterone (DHT) in the prostate.
REFERENCES
[1]
Kaplan SA, Lee RK, Chung DE, Te AE, Scherr DS, Tewari A, Vaughan ED (2012). Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5a-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol. 188(3):757-61. PMID 22818135.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.